Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Bayer
Actuate Therapeutics Inc.
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
ViroMissile, Inc.
MacroGenics
Avacta Life Sciences Ltd
Adela, Inc
Ocellaris Pharma, Inc.
Eli Lilly and Company
Var2 Pharmaceuticals
Tanabe Pharma America, Inc.
Transgene
Bayer
Actym Therapeutics, Inc.
AVM Biotechnology Inc
Valo Therapeutics Oy
Eli Lilly and Company
Sensei Biotherapeutics, Inc.
OncoC4, Inc.
Elevation Oncology
Labcorp Corporation of America Holdings, Inc
Intensity Therapeutics, Inc.
BostonGene
Cybrexa Therapeutics
Cyteir Therapeutics, Inc.
BeiGene
Taproot Health
Shanghai PerHum Therapeutics Co., Ltd.
Mundipharma Research Limited
Xencor, Inc.
Prelude Therapeutics
Gene Surgery LLC
Innolake Biopharm
TransThera Sciences (Nanjing), Inc.
DNAtrix, Inc.
Corvus Pharmaceuticals, Inc.
Prelude Therapeutics
pharmaand GmbH
NBE-Therapeutics AG
Hoffmann-La Roche
Shanghai Yunying Medical Technology
Kineta Inc.
Tempest Therapeutics
Shanghai Yunying Medical Technology
Shanghai Yunying Medical Technology
Pfizer
Prelude Therapeutics